Page 11234..1020..»

Archive for the ‘Stem Cell Therapy’ Category

Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study – SciTechDaily

Wednesday, August 4th, 2021

A study released inSTEM CELLS Translational Medicinehas confirmed the safety of a novel type of cellular therapy for knee pain caused by osteoarthritis. Conducted by a multi-institutional team of researchers in Japan who had developed the new therapy, the study was designed to confirm that their treatment which involves transplanting the patients own mesenchymal stem cells (MSCs) into the affected knee did not cause tumors.

The results showed that five years after transplantation, osteoarthritis-related tears to the knee meniscus had healed and, just as importantly, none of the patients experienced any serious side effects from the treatment. The meniscus is a crescent-shaped cartilage in the knee joint that plays a role in shock absorption. Age-related damage to the meniscus often leads to the progression of osteoarthritis of the knee.

Chronic knee pain is a major issue for the aging, affecting approximately 25 percent of all adults, according to the Centers for Disease Control and Prevention (CDC). Osteoarthritis is the most common cause of this condition in people aged 50 and older. Along with pain, which can be debilitating, knee problems can significantly affect the persons mobility and quality of life.

Knee replacement surgery is the gold standard of treatment, with the majority of people experiencing a dramatic reduction in pain and, thus, improvement in their ability to live a normal life. However, though rare, such surgery does come with risks such as the possibility of infection.

Lead investigator Mitsuru Mizuno, DVM, Ph.D. and corresponding author Ichiro Sekiya, M.D., Ph.D. Credit: AlphaMed Press

Cellular therapies are showing great potential as a less invasive way to treat difficult-to-heal knee injuries. The team behind the current study, which included researchers from Tokyo Medical and Dental University, Kyoto University and Kazusa DNA Research Institute, recently developed a therapy involving the transplantation of MSCs derived from the knees soft tissue (the synovium) into the injured meniscus. MSCs are multipotent adult stem cells present in the umbilical cord, bone marrow, fat, dental and other body tissues. Their ability to secrete biologically active molecules that exert beneficial effects on injured tissues makes them a promising target in regenerative medicine.

But some stem cell treatments have been known to cause tumors, which is why the team wanted to ensure that their therapy was free of any negative side effects. In particular, they wanted to investigate the safety of any MSCs that might show a type of chromosomal disorder called trisomy 7.

Trisomy 7 occurs frequently in patients with severe knee disease such as osteoarthritis. The detection of trisomy 7 in epithelial cells has been associated with tumor formation. However, the safety of these cells after transplantation has not been investigated. Thats what we wanted to learn from this study, said corresponding author Ichiro Sekiya, M.D., Ph. D., director and professor of the Center for Stem Cell and Regenerative Medicine (CSCRM) at Tokyo Medical and Dental University.

Mitsuru Mizuno, DVM, Ph.D., assistant professor with CSCRM, served as the studys lead investigator. He reported on the results. We recruited 10 patients for the study and transplanted their own stem cells into the affected knee joints, then followed up with MRIs over the next five years. The images revealed that tears in the patients knee meniscus were obscured three years after transplantation. We also identified trisomy 7 in three of the patients, yet no serious adverse events including tumor formation were observed in any of them.

Dr. Sekiya added, Keep in mind that these were autologous MSCs used in our study, which means that the transplanted MSCs came from the patients themselves. Any problems that might arise in the case of allogeneic cells, which are donated by someone other than the patient, still need to be determined.

Nevertheless, we believe that these data suggest that MSCs with trisomy 7 are safe for transplantation into human knees and show much promise in treating osteoarthritis.

This study highlights the ability of a patients own stem cells to potentially heal torn cartilage in the knee, said Anthony Atala, M.D., Editor-in-Chief ofSTEM CELLS Translational Medicineand director of the Wake Forest Institute for Regenerative Medicine. These outcomes suggest a potential approach that could change the overall physical health of patients who suffer from osteoarthritis and experience debilitating joint pain. We look forward to the continuation of this research to further document clinical efficacy.

Reference: Transplantation of human autologous synovial mesenchymal stem cells with trisomy 7 into the knee joint and 5 years of follow-up 3 August 2021, STEM CELLS Translational Medicine.DOI: 10.1002/sctm.20-0491

See more here:
Safety of Stem Cell Therapy for Chronic Knee Pain Confirmed in New Study - SciTechDaily

Read More...

Multiple myeloma stem cell transplant: What happens and more? – Medical News Today

Wednesday, August 4th, 2021

One potential treatment for multiple myeloma is a stem cell transplant. This involves a person receiving high-dose chemotherapy to kill the cancer cells in the bone marrow. This can also kill healthy cells inside the bone marrow, so the person then receives new, healthy, blood-forming stem cells via a transplant.

The healthy stem cells that a medical professional transplants into a person can come from the person themselves or from a donor. If the stem cells come from the person it is called an autologous transplant. If they come from or a donor it is called an allogeneic transplant.

A stem cell transplant (SCT) may cause multiple myeloma to go into remission, but medical professionals do not consider it to be a cure.

This article looks at types of SCTs, who should have one, what to expect from the procedure, and side effects. It also looks at how effective SCTs are, the recovery and outlook, and alternatives.

There are two types of SCT that people can receive for multiple myeloma:

In an autologous transplant, a doctor removes a persons own stem cells from their bone marrow or peripheral blood. They then store the cells until they need them for the procedure.

A doctor will give the person high-dose chemotherapy, sometimes with radiation, to kill the cancer cells. The doctor will then give the stored, healthy stem cells to the person through a catheter, similar to a blood transfusion.

This treatment is common for people with multiple myeloma. The cancer often returns, so the procedure is not a cure, but it can make a persons cancer go into remission for a period of time that may last a number of years.

Doctors sometimes recommend that a person has two autologous transplants. These will often take place 612 months apart. This is called a tandem transplant. Research shows that this approach can be more effective than a single transplant. However, a tandem transplant can cause more side effects and may be riskier.

In an allogeneic transplant, a person receives blood-forming stem cells from a donor.

A person will experience the best results if they are given cells that closely match their own type. For this reason, the best donors are often closely related to the person.

Allogeneic transplants carry a higher risk than autologous transplants. However, some studies suggest they may provide better results. This is because the transplanted cells from the donor may actually help destroy myeloma cells. This is called a graft tumor effect.

Studies have shown that people who receive allogeneic transplants may not do as well as those who receive autologous transplants in the short term. Allogeneic transplants are not considered a standard treatment for multiple myeloma, however, medical professionals may give them as part of a clinical trial.

People who are young and are in the early stages of cancer, as well as those who have not already gone through much treatment, often handle STCs better. For this reason, some transplant centers set age limits. This may not be especially helpful to people with multiple myeloma, who are on average 65 years old at diagnosis.

People with other major health issues may not be eligible for STCs. These can include:

A doctor is likely to perform a variety of tests on the person first, to see if they will be able to handle the process of an STC. These may include:

A doctor is also likely to discuss the related costs a person might incur and the scope of their health insurance coverage. STCs can be expensive, and may cost between $140,792 and $289,283.

Medicare covers part of the costs of two types of FDA-approved stem cell therapy, or transplants. These types are allogeneic hematopoietic stem cell transplantation (Allo-SCT) and autologous stem cell transplantation (Au-SCT).

The transplant team at the hospital will decide if the person needs to have the transplant in the hospital or in an outpatient center. If the person needs to be in hospital, they may have to start their stay the day before any chemotherapy or radiation treatment begins.

Conditioning treatment is also known as bone marrow preparation, pre-transplant treatment, or myeloablation. It usually involves a doctor giving the person high-dose chemotherapy treatment, radiation treatment, or both. This treatment usually takes 12 weeks.

Conditioning takes place for several reasons. These include:

Conditioning treatment will be different for each person, and depends on their cancer, any radiation, or chemotherapy treatment they have had in the past, and the type of transplant they are having.

This phase of the treatment can be difficult and uncomfortable, as doctors will use high doses of chemotherapy and radiation. It can make people feel very ill, and it may take months for them to recover.

Side effects of the preparation treatment can include:

After the conditioning treatment, a doctor will give a person a couple of days to rest before giving them the new stem cells.

A doctor will give the stem cells through a central venous catheter, similar to a blood transfusion. The doctor may also give the person drugs to reduce the risk of a reaction to preservatives in the stem cells, if they are using previously frozen stem cells.

The length of the process depends on how much liquid the stem cells are in. This part of the process is painless, and people are awake for it.

Side effects from the transplant itself are rare, and are usually mild.

The preserving agent used when the stem cells are frozen may cause side effects. These may include a person tasting garlic, and their body smelling different or unpleasant. These side effects last for a few days and then go away.

Other side effects can include:

The most serious side effect from an allogeneic transplant is called graft-versus-host disease (GVHD). This occurs when the new immune cells from the donor attack the persons tissue, as they see it as a harmful foreign body. GVHD can be life-threatening.

A 2019 review reports that SCTs improve the survival rate of people compared with treatment that just involves chemotherapy.

As complementary treatments have improved, SCTs have become increasingly effective at treating certain types of cancer.

A persons blood count should return to normal in about 26 weeks. They should visit the transplant center daily for a number of weeks.

A person may have to take antibiotics to prevent infection while their red and white blood cell count is still low.

People may experience side effects, as well as feelings of anxiety, depression, joy, or anger. People may also require a period of rehabilitation following their STC.

People often feel tired, and experience poor mental and physical health following an STC. Doctors will monitor people carefully during the rehabilitation period. They may suggest daily or weekly blood tests and exams.

People may also require platelet and blood transfusions, antibiotics, and other treatments during rehabilitation.

A person may need to see their transplant team frequently, even daily, for a period that may last between 612 months. During this time, they may experience problems including:

During what may be a difficult period of rehabilitation and recovery, a person should be in close contact with their transplant team for support.

Types of treatment will depend on the type of cancer the person has, as well as their preferences, and their ability to withstand certain treatments.

The use of medication to destroy cancer cells is called systemic therapy. Doctors give this type of treatment through the bloodstream to reach cancer cells throughout the body.

An oncologist may prescribe systemic therapy for multiple myeloma. Systemic therapy may include:

Multiple myeloma is a cancer that affects the plasma cells in the bone marrow, causing them to grow and divide more than usual. This crowds out healthy cells, causing tumors to form in the bone marrow.

Doctors may treat multiple myeloma with stem cell transplants. This involves killing cancer cells with high-dose chemotherapy or radiation, then giving a person new stem cells. The two types of stem cell transplant are an autologous transplant, using stem cells from the person, or an allogeneic transplant, using donor cells. Autologous transplants are much more common.

People with kidney, heart, and lung problems, or people who have had a lot of cancer treatments previously, may not handle a stem cell transplant well. Young people who have no other illnesses are best suited to a stem cell transplant.

A stem cell transplant can increase a persons chances of survival, but it is not a cure, and may only send the cancer into remission.

People may experience side effects. The worst side effects are likely to come from the chemotherapy and radiation. Side effects of the actual transfusion are rare and usually mild.

Recovery can take a year or more. People should remain in close contact with their transplant team and go for regular check-ups.

Alternative treatments to stem cell transplants include systemic treatment, which involves taking medication to kill the cancer cells.

Excerpt from:
Multiple myeloma stem cell transplant: What happens and more? - Medical News Today

Read More...

Animal Stem Cell Therapy Market Research 2021-2027 With Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, US Stem Cell The Manomet Current – The…

Wednesday, August 4th, 2021

The updated report on the Animal Stem Cell Therapy market gives a precise analysis of the value chain assessment for the review period of 2021 to 2027. The research includes an exhaustive evaluation of the administration of the key market companies and their revenue-generating business strategies adopted by them to drive sustainable business. The Animal Stem Cell Therapy industry report further enlists the market shortcomings, stability, growth drivers, restraining factors, opportunities for the projected timeframe.

Get Sample Report with Latest Industry Trends Analysis: http://www.a2zmarketresearch.com/sample?reportId=526842

The top companies in this report include:

Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, U.S. Stem Cell, Inc, VetCell Therapeutics, Celavet Inc., Magellan Stem Cells, Kintaro Cells Power, Animal Stem Care, Animal Cell Therapies, Cell Therapy Sciences, Animacel

The Global Animal Stem Cell Therapy market is expected to register a prominent% of market expansion during the review period owing to the largest market value in 2019. The market study provides a measure of the effectiveness of the product, real-time Animal Stem Cell Therapy market scenario, along custom ease. The study further offers market analysis, strategies and planning, R & D landscape, target audience management, market potential, due diligence, and competitive landscape.

Market Segmentation

Segment By Type

Dogs Stem Cell Therapy, Horses Stem Cell Therapy, Others Animals

Segment By Application

Veterinary Hospitals, Research Organizations

Scope of the report

A thorough analysis of statistics about the current as well as emerging trends offers clarity regarding the Animal Stem Cell Therapy market dynamics. The report includes Porters Five Forces to analyze the prominence of various features such as the understanding of both the suppliers and customers, risks posed by various agents, the strength of competition, and promising emerging businesspersons to understand a valuable resource. Also, the report spans the Animal Stem Cell Therapy research data of various companies, benefits, gross margin, strategic decisions of the worldwide market, and more through tables, charts, and infographics.

The Animal Stem Cell Therapy report highlights an all-inclusive assessment of the revenue generated by the various segments across different regions for the forecast period, 2021 to 2027. To leverage business owners, gain a thorough understanding of the current momentum, the Animal Stem Cell Therapy research taps hard to find data on aspects including but not limited to demand and supply, distribution channel, and technology upgrades. Principally, the determination of strict government policies and regulations and government initiatives building the growth of the Animal Stem Cell Therapy market offers knowledge of what is in store for the business owners in the upcoming years.

Request For Customized Report: http://www.a2zmarketresearch.com/enquiry?reportId=526842

Geographic analysis

The global Animal Stem Cell Therapy market has been spread across North America, Europe, Asia-Pacific, the Middle East and Africa, and the rest of the world.

COVID-19 Impact Analysis

The pandemic of COVID-19 has emerged in lockdown across regions, line limitations, and breakdown of transportation organizations. Furthermore, the financial vulnerability Animal Stem Cell Therapy Market is a lot higher than past flare-ups like the extreme intense respiratory condition (SARS), avian influenza, pig influenza, bird influenza, and Ebola, inferable from the rising number of contaminated individuals and the vulnerability about the finish of the crisis. With the rapid rising cases, the worldwide Animal Stem Cell Therapy refreshments market is getting influenced from multiple points of view.

The accessibility of the labor force is by all accounts disturbing the inventory network of the worldwide Animal Stem Cell Therapy drinks market as the lockdown and the spread of the infection are pushing individuals to remain inside. The presentation of the Animal Stem Cell Therapy makers and the transportation of the products are associated. If the assembling movement is stopped, transportation and, likewise, the store network additionally stops. The stacking and dumping of the items, i.e., crude materials and results (fixings), which require a ton of labor, is likewise vigorously affected because of the pandemic. From the assembling plant entryway to the stockroom or from the distribution center to the end clients, i.e., application ventures, the whole Animal Stem Cell Therapy inventory network is seriously compromised because of the episode.

The research provides answers to the following key questions:

Buy Exclusive Report: http://www.a2zmarketresearch.com/buy?reportId=526842

Contact Us:

Roger Smith

1887 WHITNEY MESA DR HENDERSON, NV 89014

sales@a2zmarketresearch.com

+1 775 237 4147

Read more:
Animal Stem Cell Therapy Market Research 2021-2027 With Medivet Biologics LLC, VETSTEM BIOPHARMA, J-ARM, US Stem Cell The Manomet Current - The...

Read More...

Global Stem Cell Therapy Market to witness exponential proliferation during 2020-2026 The Manomet Current – The Manomet Current

Wednesday, August 4th, 2021

TheGlobal Stem Cell Therapy Market To Garner Immense Returns Over 2020-2026A fundamental outline of theStem Cell Therapy Marketniche is presented by the Stem Cell Therapy Market report that entails definitions, classifications, applications together with industry chain framework. TheStem Cell Therapy Marketreport provides a far-reaching evaluation of necessary market dynamics and the latest trends. It also highlights the regional market, the prominent market players, as well as several market segments [Product, Applications, End-Users, and Major Regions], and sub-segments with a wide-ranging consideration of numerous divisions with their applications.

FREE | Request Sample is Available @https://www.zionmarketresearch.com/sample/stem-cell-therapy-market

Some of the Major Market Players Are:

Anterogen Co., Ltd., RTI SurgicalInc., Pharmicell Co., Ltd., MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., NuVasiveInc., and AlloSource.

Further, the report acknowledges that in these growing and promptly enhancing market circumstances, the most recent advertising and marketing details are very important to determine the performance in the forecast period and make essential choices for profitability and growth of the Stem Cell Therapy Market. In addition, the report encompasses an array of factors that impact the growth of the Stem Cell Therapy Market in the forecast period. Further, this specific analysis also determines the impact on the individual segments of the market.

Furthermore, the study assessed major market elements, covering the cost, capacity utilization rate, growth rate, capacity, production, gross, usage, revenue, export, supply, price, market share, gross margin, import, and demand. In addition, the study offers a thorough segmentation of the global Stem Cell Therapy Market on the basis of geography [ Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] , technology, end-users, applications, and region.

The Stem Cell Therapy Market report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments.

Download Free research report Brochure @https://www.zionmarketresearch.com/requestbrochure/stem-cell-therapy-market

The Stem Cell Therapy Market report is an appropriate compilation of all necessary data for the residential, industrial. & commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projected as well as the prevailing trends in the Stem Cell Therapy Market. Apart from this, the report also provides insightful particulars of the existing policies, laws, together with guidelines.

Promising Regions & Countries Mentioned In The Stem Cell Therapy Market Report:

Chapters Covered in Research Report are :

Chapter 1,2 :The goal of global Stem Cell Therapy Market covering the market introduction, product image, market summary and development scope.

Chapter 3, 4 :Global Market Competitions by Manufacturers, Sales Volume and Market Profit.

Chapter 5,6,7:Global Supply (Production), Consumption, Export, Import by Regions like United States, Asia-Pacific, China, India, Japan. Conducts the region-wise study of the market based on the sales ratio in each region, and market share from 2021to 2027

Chapter 8,9,10:Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributors/Traders

Chapter 11,12 :Market information and study conclusions, appendix and data sources.

The market report also identifies further useful and usable information about the industry mainly includes Stem Cell Therapy Market development trend analysis, investment return and feasibility analysis. Further, SWOT analysis is deployed in the report to analyze the key global market players growth in the Stem Cell Therapy Market industry

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/stem-cell-therapy-market

Purposes Behind Buying Stem Cell Therapy Market Report:-

Key questions answered in this comprehensive study Global Stem Cell Therapy Market Size, Status and Forecast 2026

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Read More Report:Clinical Risk Grouping Solutions Market

See the original post here:
Global Stem Cell Therapy Market to witness exponential proliferation during 2020-2026 The Manomet Current - The Manomet Current

Read More...

FDA gives speedy review to Bayer’s Parkinson’s stem cell therapy – – pharmaphorum

Wednesday, July 21st, 2021

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinsons disease which is currently in early-stage clinical testing.

The FDA designation allows for benefits such as more frequent meetings and communication with the regulator during clinical development, and a truncated six-month review time.

Those are all considerations for the future as the first patients only started to be treated with DA01 in a phase 1 trial aimed primarily at showing the safety of the therapy, which is trying to replenish the dopaminergic neurons that progressively die away in Parkinsons and lead to slow, laboured movement, tremors and other symptoms.

The therapy involves implantation of dopamine-producing cells under general anaesthesia into a part of the brain called the putamen, which is particularly affected by neuron loss in Parkinsons and is responsible for regulating movement as well as some types of learning.

Patients take immune-suppressing drugs to prevent their body rejecting the transplanted cells, and the safety and tolerability of the procedure as well as the ability of the transplant to survive will be monitored for two years.

BlueRock is also hoping to demonstrate some evidence of efficacy, and will look at clinical measures such as motor function over the same time period. It is the first trial in the US to study pluripotent stem cell-derived dopaminergic neurons in patients with Parkinsons, according to the company.

The first patient in the trial, which will eventually enrol 10 subjects with advanced Parkinsons, was treated at Memorial Sloan Kettering Cancer Centre in June, and others will be recruited at Weill Cornell Medical Centre, the University of California, Irvine, and the University of Toronto.

Our objective is to use authentic cells, to have them integrate entirely into the brain and restore lost physiologic function, said BlueRock chief executive Emile Nuwaysir, as the first patient was treated.

If successful, this new therapeutic modality could have implications for the Parkinsons community and beyond, he added.

Bayer took control of BlueRock in 2019, three years after backing the formation of the company as joint venture with private equity group Versant, in a deal that valued the biotech at $1 billion.

DA01 is Bluerocks lead cell therapy programme, but the company is also working on treatments for other neurological disorders, degenerative heart disease, and autoimmune disorders.

Bayer is also developing a gene therapy for Parkinsons originated by Asklepios Bio (AskBio), which it acquired for $2 billion upfront last year with another $2 billion tied to milestones, and has pledged to make cell and gene therapies a pillar of its R&D strategy.

See more here:
FDA gives speedy review to Bayer's Parkinson's stem cell therapy - - pharmaphorum

Read More...

Stem Cell Therapy Market Analysis of Key Players, End User, Demand and Consumption By 2026 26 Sports – 2×6 Sports

Wednesday, July 21st, 2021

The report published on the Stem Cell Therapy Market Analysis of Key Players, End User, Demand and Consumption By 2026 by Zion Market Research facilitates a closer outlook on opportunities, revenue growth, and current market trends. The report is focused to offer qualitative and quantitative analysis of dynamics and market opportunities prevailing during the forecast period. Also, the report encompasses an in-depth study on the prominent leaders in theStem Cell Therapy Market.

The Leading Market Players Covered in this Report are:

Anterogen Co., Ltd., RTI SurgicalInc., Pharmicell Co., Ltd., MEDIPOST Co., Ltd., JCR Pharmaceuticals Co., Ltd., Holostem Terapie Avanzate S.r.l., NuVasiveInc., and AlloSource.

The market report additionally gives a to-the-point evaluation of the techniques and plans of action that are being executed by the players and companies to contribute to the global Stem Cell Therapy Market growth. Some of the most conspicuous measures taken by the organizations are partnerships, mergers & acquisitions, and collaborations to extend their overall reach. The players are likewise presenting newer product varieties in the market to improve the product portfolio by embracing the new innovation and carrying out it in their business.

Get Sample PDF Brochure @https://www.zionmarketresearch.com/sample/stem-cell-therapy-market

The report provides extensive insights into the key strategies and market development dynamics along with the macro and micro factors in the current market landscape. Also, the report comprises the Covid-19 and post-Covid-19 market landscape to let users identify the upcoming patterns and trends in the global Stem Cell Therapy Market. Our analysts have prepared the report as an indispensable guide for enabling our customers to take qualitative decisions and reap the best results out of it.

The report is segregated into different sections of which few are overview, growth factors, segmentation, regional analysis, and competitive analysis. The only aim to bifurcate the report into different sections is to put forth an in-depth assessment of each parameter and let our users understand the most probable and even the finest trend prevailing in the current landscape. Also, the structure of a report is curated to reveal the future trends and opportunities in the global Stem Cell Therapy Market in the forthcoming years.

This Research Help Grow Your Business [Download free Sample PDF of Research Report]

The overview section reveals the potential, opportunities, and scope of the Stem Cell Therapy Market along with its market size and volume. Also, the section encompasses an in-depth study on value chain analysis and the core working of the market. The growth factor segment elaborates the financial position, technology dynamics, and product portfolio expected in the forthcoming year. Also, the segmentation section bifurcates the whole market landscape into different classes to identify the market size and volume of each segment. However, the regional analysis segment reveals the extensive potential of each region in the global Stem Cell Therapy Market along with its size and volume.

Our analysts have tried to maintain the highest level of transparency and accuracy in the report. Also, the report offers business intelligence solutions for helping our clients to achieve a competitive edge in the global Stem Cell Therapy Market. Moreover, it will help our users to curate effective business strategies to promulgate the growth rate of their business in the forthcoming years. However, all the statistical and quantitative analysis mentioned in the report reflects the real-time data. It covers all the market landscapes to help users understand the present positioning of the global Stem Cell Therapy Market along with the probable market trends in the future.

Inquire More about Report:https://www.zionmarketresearch.com/inquiry/stem-cell-therapy-market

Moving to the drivers and restraints, one will be given all factors that are indirectly or directly helping the development of the global Stem Cell Therapy Market. To get to know the markets development measurements, it is important to evaluate the drivers of the market. Furthermore, the report likewise analyses the current patterns alongside new and plausible growth openings for the global market. Additionally, the report incorporates the components that can restrict the market growth during the forecast period. Understanding these elements is also mandatory as they help in grasping the markets shortcomings.

Primary and secondary methodologies are being utilized by the research analysts to gather the information. Along these lines, this global Stem Cell Therapy Market report is planned at guiding the readers to a superior, clearer viewpoint and information about the global market.

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia

View post:
Stem Cell Therapy Market Analysis of Key Players, End User, Demand and Consumption By 2026 26 Sports - 2x6 Sports

Read More...

NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy – Business Wire

Thursday, June 24th, 2021

SEATTLE--(BUSINESS WIRE)--NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced the launch of the nCounter Stem Cell Characterization Panel for the analysis and optimization of stem cell lines used in the development of potential novel therapeutics.

Recent breakthroughs in stem cell therapy, regenerative medicine, and CRISPR engineering have advanced the development of promising new treatments for debilitating diseases across a broad range of research areas, including neurological and cardiovascular disease, vision loss, and certain types of cancers. However, one of the biggest challenges with stem cell research is the high variability found within the development and manufacturing process that impacts the ability of the stem cells to differentiate and function. The new nCounter Stem Cell Characterization panel measures the eight essential components of stem cell biology and provides a novel, standardized assay for evaluating factors that influence and determine viability, functionality, and pluripotency.

"The simple, automated workflow and highly reproducible, digital results make the nCounter system an excellent fit for all types of stem cell applications," said Chad Brown, senior vice president of Sales and Marketing at NanoString. "With this panel, researchers have a powerful new tool that can quickly assess stem cell health to advance development efforts and optimize stem cell production, achieving robust results in less than 24 hours."

"The Process Development team at ARMI-BioFabUSA is very excited to use the nCounter Stem Cell Characterization panel across a number of our projects where we are developing human tissues composed of mature cells differentiated from stem cells. The Stem Cell Characterization Panel will give us greater insight into the differentiation status of our cells and the success of our current process development and manufacturing runs," said Damian Hile, senior process development scientist at Advanced Regenerative Manufacturing Institute-BioFabUSA (ARMI-BioFabUSA).

The novel 770 gene panel is available for humans and mice and was designed at NanoString with input from leading stem cell experts. To learn more about the nCounter Stem Cell Characterization Panel, visit NanoString at the virtual 2021 ISSCR Conference June 21-26. In addition, NanoString is sponsoring the Cellular Identity: Pluripotency Dynamics session, with Joseph Beechem, Ph.D., chief scientific officer at NanoString.

To learn more about the panel and how the development of the panel can expedite stem cell research, visit the Brief nCounters stem cell experience.

About ARMI-BioFabUSA

The Advanced Regenerative Manufacturing Institute (ARMI), headquartered in Manchester, NH, is an organization funded by the United States Department of Defense. ARMI's mission is to make practical the large-scale manufacturing of engineered tissues and tissue-related technologies to benefit existing industries and grow new ones. ARMI brings together a consortium of over 150 partners from across the industry, government, academia and the non-profit sector to develop next-generation manufacturing processes and technologies for cells, tissues and organs. For more information on ARMI-BioFabUSA, please visit http://www.ARMIUSA.org.

About NanoString Technologies, Inc.

NanoString Technologies is a leading provider of life science tools for discovery and translational research. The company's nCounter Analysis System is used in life sciences research and has been cited in more than 4,300 peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's GeoMx Digital Spatial Profiler enables highly-multiplexed spatial profiling of RNA and protein targets in a variety of sample types, including FFPE tissue sections.

For more information, please visit http://www.nanostring.com.

NanoString, NanoString Technologies, the NanoString logo, GeoMx, and nCounter are trademarks or registered trademarks of NanoString Technologies, Inc. in various jurisdictions.

Read more:
NanoString Launches nCounter Stem Cell Characterization Panel to Advance the Development of Stem Cell Therapy - Business Wire

Read More...

Adipose Tissue Derived Stem Cell Therapy Market New Innovation and Perception 2028 AlloCure, Antria, Celgene, Cellleris SA, Corestem, Intrexon,…

Thursday, June 24th, 2021

Adipose Tissue Derived Stem Cell Therapy Market study by The Insight Partners provides details about the market dynamics affecting the market, Market scope, Market segmentation and overlays shadow upon the leading market players highlighting the favorable competitive landscape and trends prevailing over the years.

The research report provides deep insights into the global market revenue, parent market trends, macro-economic indicators, and governing factors, along with market attractiveness per market segment. The report provides an overview of the growth rate of the Adipose Tissue Derived Stem Cell Therapy market during the forecast period, i.e., 20212028. Most importantly, the report further identifies the qualitative impact of various market factors on market segments and geographies. The research segments the market to offer more clarity regarding the industry, the report takes a closer look at the current status of various factors including but not limited to supply chain management, niche markets, distribution channel, trade, supply, and demand and production capability across different countries.

The report profiles the key players in the industry, along with a detailed analysis of their individual positions against the global landscape. The study conducts SWOT analysis to evaluate strengths and weaknesses of the key players in the Adipose Tissue Derived Stem Cell Therapy market. The researcher provides an extensive analysis of the Adipose Tissue Derived Stem Cell Therapy market size, share, trends, overall earnings, gross revenue, and profit margin to accurately draw a forecast and provide expert insights to investors to keep them updated with the trends in the market.

Get Sample Report of Adipose Tissue Derived Stem Cell Therapy Market Report @ https://www.theinsightpartners.com/sample/TIPRE00014843/

(*If you have any special requirements, please let us know and we will offer you the report as you want.)

The Adipose Tissue-derived Stem Cell Therapy Market is growing due to increasing use of regenerative medicine in disease treatment and increasing private and public funding for stem cell therapy. However, high cost associated with stem cell processing hampers growth of this market.

Competitive scenario:

The study assesses factors such as segmentation, description, and applications of Adipose Tissue Derived Stem Cell Therapy industries. It derives accurate insights to give a holistic view of the dynamic features of the business, including shares, profit generation, thereby directing focus on the critical aspects of the business.

The final report will add the analysis of the Impact of Covid-19 in this report Adipose Tissue Derived Stem Cell Therapy Market.

Adapting to the recent novel COVID-19 pandemic, the impact of the COVID-19 pandemic on the global Adipose Tissue Derived Stem Cell Therapy Market is included in the present report. The influence of the novel coronavirus pandemic on the growth of the Adipose Tissue Derived Stem Cell Therapy Market is analyzed and depicted in the report.

Some of the companies competing in the Adipose Tissue Derived Stem Cell Therapy Market are

Segmentation

The Adipose Tissue-derived Stem Cell Therapy market is segmented on the basis of cell type, product, disease and end user. Based on cell type, the market is segmented as autologous stem cells, allogeneic stem cells. On the basis of product, the market is categorized as cell line and culture media. Based on disease the market is segmented into cancer, obesity, wounds and injuries, musculoskeletal diseases, cardiovascular diseases and others. Based on end user the market is segmented into hospitals and trauma centers , cell banks and tissue banks , research laboratories and academic institutes and other The market is also segmented according to region. The Adipose Tissue Derived Stem Cell Therapy Market has been segmented into Latin America, North America, Asia Pacific, Europe, and the Middle East & Africa on the basis of region

Research Methodology

The report has its roots definitely set in thorough strategies provided by the proficient data analysts. The research methodology involves the collection of information by analysts only to have them studied and filtered thoroughly in an attempt to provide significant predictions about the market over the review period. The research process further includes interviews with leading market influencers, which makes the primary research relevant and practical. The secondary method gives a direct peek into the demand and supply connection. The market methodologies adopted in the report offer precise data analysis and provides a tour of the entire market. Both primary and secondary approaches to data collection have been used. In addition to these, publicly available sources such as SEC filings, annual reports, and white papers have been used by data analysts for an insightful understanding of the market. The research methodology clearly reflects an intent to extract a comprehensive view of the market by having it analyzed against many parameters. The valued inputs enhance the report and offer an edge over the peers.

Drivers & Constraints

The Adipose Tissue Derived Stem Cell Therapy Market rests united with the incidence of leading players who keep funding to the markets growth significantly every year. The report studies the value, volume trends, and the pricing structure of the market so that it could predict maximum growth in the future. Besides, various suppressed growth factors, restraints, and opportunities are also estimated for the advanced study and suggestions of the market over the assessment period.

Adipose Tissue Derived Stem Cell Therapy Market Segmented by Region/Country: North America, Europe, Asia Pacific, Middle East & Africa, and Central & South America

Interested in purchasing this Report? Click here @ https://www.theinsightpartners.com/buy/TIPRE00014843/

Thanks for reading this release; you can also customize this report to get select chapters or region-wise coverage with regions such as Asia, North America, and Europe.

About Us:

The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We are a specialist in Technology, Healthcare, Manufacturing, Automotive and Defense.

Contact US:

Call: +1-646-491-9876

Email: sales@theinsightpartners.com

View original post here:
Adipose Tissue Derived Stem Cell Therapy Market New Innovation and Perception 2028 AlloCure, Antria, Celgene, Cellleris SA, Corestem, Intrexon,...

Read More...

Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene…

Thursday, June 24th, 2021

REDWOOD CITY, Calif. and NEW YORK and BASEL, Switzerland, June 21, 2021 /PRNewswire/ --Jasper Therapeutics, Inc., a biotechnology company focused on hematopoietic cell transplant therapies, andAruvant Sciences, a private company focused on developing gene therapies for rare diseases, today announced that they have entered a non-exclusive research collaboration to evaluate the use of JSP191, Jasper's anti-CD117 monoclonal antibody, as a targeted, non-toxic conditioning agent with ARU-1801, Aruvant's investigational lentiviral gene therapy for sickle cell disease (SCD). The objective of the collaboration is to evaluate the use of JSP191 as an effective and more tolerable conditioning agent that can expand the number of patients who can receive ARU-1801, a potentially curative treatment for SCD.

"This research collaboration with Aruvant is the first to use a clinical-stage antibody-based conditioning agent and a novel clinical-stage gene therapy, giving this combination a clear advantage by moving beyond the harsh conditioning agents currently used for gene therapy and establishing this next-generation potentially curative treatment as a leader in sickle cell disease," said Kevin N. Heller, M.D., executive vice president, research and development of Jasper. "Our goal is to establish JSP191 as a potential new standard of care conditioning agent, broadly in autologous gene therapy and allogeneic hematopoietic stem cell transplantation."

Gene therapies and gene editing technologies generally require that a patient's own hematopoietic stem cells first be depleted from the bone marrow to facilitate the engraftment of the new, gene-modified stem cells through a process called conditioning. Other investigational gene therapies and gene editing approaches in SCD use a high-dose chemotherapy such as busulfan for the conditioning regimen, which can place patients at prolonged risk for infection and bleeding, secondary malignancy and infertility. ARU-1801 is currently the only gene therapy that has demonstrated durable efficacy using both a lower dose of chemotherapy and a different agent than busulfan with a more limited side effect profile. The Aruvant-Jasper partnership is focused on evaluating the potential of using JSP191, a highly targeted anti-CD117 (stem cell factor receptor) monoclonal antibody agent, as the foundationof a novel conditioning regimen for use in combination with ARU-1801 to further reduce the negative side effects while maintaining efficacy.

"The unique attributes of ARU-1801 enable us to bring a potentially curative one-time therapy to individuals with sickle cell disease that can be delivered in the safest way possible," said Will Chou, M.D., Aruvant chief executive officer. "By partnering with Jasper to evaluate the use of JSP191 with ARU-1801, we are one step closer to developing a next-generation definitive therapy with an even more patient-friendly conditioning regimen. We believe that this combination may be able to further expand the number of patients who can benefit from ARU-1801 in the future, including potentially those with more moderate disease."

About JSP191 JSP191 is a humanized monoclonal antibody in clinical development as a conditioning agent that blocks stem cell factor receptor signaling leading to clearance of hematopoietic stem cells from bone marrow, creating an empty space for donor or gene-corrected transplanted stem cells to engraft. While hematopoietic cell transplantation can be curative for patients, its use is limited because standard high dose myeloablative conditioning is associated with severe toxicities and standard low dose conditioning has limited efficacy. To date, JSP191 has been evaluated in more than 90 healthy volunteers and patients. It is currently enrolling in two clinical trials for myelodysplastic syndromes (MDS)/acute myeloid leukemia (AML) and severe combined immunodeficiency (SCID) and expects to begin enrollment in four additional studies in 2021 for severe autoimmune disease, sickle cell disease, chronic granulomatous disease and Fanconi anemia patients undergoing hematopoietic cell transplantation.

About ARU-1801 ARU-1801 is designed to address the limitations of current curative treatment options, such as low donor availability and the risk of graft-versus-host disease (GvHD) seen with allogeneic stem cell transplants. Unlike investigational gene therapies and gene editing approaches which require fully myeloablative conditioning, the unique characteristics of ARU-1801 allow it to be given with reduced intensity conditioning ("RIC"). Compared to myeloablative approaches, the lower dose chemotherapy regimen underlying RIC has the potential to reduce not only hospital length of stay, but also the risk of short- and long-term adverse events such as infection and infertility. Preliminary clinical data from the MOMENTUMstudy, an ongoing Phase 1/2 trial of ARU-1801 in patients with severe sickle cell disease, demonstrate continuing durable reductions in disease burden.

The MOMENTUM Study Aruvant is conducting the MOMENTUM study, which is evaluating ARU-1801, a one-time potentially curative investigational gene therapy for patients with SCD. This Phase 1/2 study is currently enrolling participants, and information may be found at momentumtrials.comwhich includes a patient brochure, an eligibility questionnaireand information for healthcare providers.

About Jasper Therapeutics Jasper Therapeutics is a biotechnology company focused on the development of novel curative therapies based on the biology of the hematopoietic stem cell. The company is advancing two potentially groundbreaking programs. JSP191, a first-in-class anti-CD117 monoclonal antibody, is in clinical development as a conditioning agent that clears hematopoietic stem cells from bone marrow in patients undergoing a hematopoietic cell transplantation. It is designed to enable safer and more effective curative allogeneic and autologous hematopoietic cell transplants and gene therapies. In parallel, Jasper Therapeutics is advancing its preclinical engineered hematopoietic stem cell (eHSC) platform, which is designed to overcome key limitations of allogeneic and autologous gene-edited stem cell grafts. Both innovative programs have the potential to transform the field and expand hematopoietic stem cell therapy cures to a greater number of patients with life-threatening cancers, genetic diseases and autoimmune diseases than is possible today. For more information, please visit us at jaspertherapeutics.com.

About Aruvant Sciences Aruvant Sciences, part of the Roivant family of companies, is a clinical-stage biopharmaceutical company focused on developing and commercializing gene therapies for the treatment of rare diseases. The company has a talented team with extensive experience in the development, manufacturing and commercialization of gene therapy products. Aruvant has an active research program with a lead product candidate, ARU-1801, in development for individuals suffering from sickle cell disease (SCD). ARU-1801, an investigational lentiviral gene therapy, is being studied in a Phase 1/2 clinical trial, the MOMENTUM study, as a one-time potentially curative treatment for SCD. Preliminary clinical data demonstrate engraftment of ARU-1801 and amelioration of SCD is possible with one dose of reduced intensity chemotherapy. The company's second product candidate, ARU-2801, is in development to cure hypophosphatasia, a devastating, ultra-orphan disorder that affects multiple organ systems and leads to high mortality when not treated. Data from pre-clinical studies with ARU-2801 shows durable improvement in disease biomarkers and increased survival. For more information on the ongoing ARU-1801 clinical study, please visit http://www.momentumtrials.comand for more on the company, please visit http://www.aruvant.com. Follow Aruvant on Facebook, Twitter @AruvantSciencesand on Instagram @Aruvant_Sciences.

About Roivant Roivant's mission is to improve the delivery of healthcare to patients by treating every inefficiency as an opportunity. Roivant develops transformative medicines faster by building technologies and developing talent in creative ways, leveraging the Roivant platform to launch Vants nimble and focused biopharmaceutical and health technology companies. For more information, please visit http://www.roivant.com.

SOURCE Aruvant Sciences andJasper Therapeutics

Home

See the original post:
Jasper Therapeutics and Aruvant Announce Research Collaboration to Study JSP191, an Antibody-Based Conditioning Agent, with ARU-1801, a Novel Gene...

Read More...

Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 – GlobeNewswire

Thursday, June 24th, 2021

New York, June 23, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Nerve Repair and Regeneration Devices Industry" - https://www.reportlinker.com/p05957490/?utm_source=GNW The rapid rise in the incidence of nerve injuries worldwide, increasing prevalence of various neurological disorders, especially in the expanding elderly population, and development of advanced technology-based nerve repair and regeneration products are fueling growth in the global market. The constant increase in incidence of nerve injuries is leading to high demand for nerve repair and regeneration products. The growing incidence of chronic nervous system disorders such as Parkinson`s and Alzheimer`s disease is also driving demand for nerve repair and regeneration procedures and devices. There is also increased funding for clinical trials aimed at development of effective and safe therapies for treatment of various neurological disorders. Initiatives such as stem cells in umbilical blood infusion for cerebral palsy; and the use of Polyethylene glycol (PEG) drug for promoting axonal fusion technique for repairing peripheral nerve injuries are favoring market growth.

- Amid the COVID-19 crisis, the global market for Nerve Repair and Regeneration Devices estimated at US$6.6 Billion in the year 2020, is projected to reach a revised size of US$11.8 Billion by 2026, growing at a CAGR of 10% over the analysis period. Neurostimulation & Neuromodulation Devices, one of the segments analyzed in the report, is projected to grow at a 9.7% CAGR to reach US$10.9 Billion by the end of the analysis period. After a thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Biomaterials segment is readjusted to a revised 11.7% CAGR for the next 7-year period. This segment currently accounts for a 13.8% share of the global Nerve Repair and Regeneration Devices market. The neurostimulation and neuromodulation devices segment growth will be fueled by rising incidence of peripheral nerve injuries, development of technologically advanced products and favorable reimbursement scenario. Within the segment, internal neurostimulation and neuromodulation devices category is being driven due to the devices` ability to lower occurrence of post-surgical complications and reducing duration of hospitalization. Biomaterials segment is expected to witness high growth, driven by broadening application range, increased availability of government funding for innovations, and development of advanced products.

The U.S. Market is Estimated at $2.2 Billion in 2021, While China is Forecast to Reach $1.8 Billion by 2026

- The Nerve Repair and Regeneration Devices market in the U.S. is estimated at US$2.2 Billion in the year 2021. The country currently accounts for a 30.45% share in the global market. China, the world`s second largest economy, is forecast to reach an estimated market size of US$1.8 Billion in the year 2026 trailing a CAGR of 13% through the analysis period. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 7.7% and 8.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 9.2% CAGR while Rest of European market (as defined in the study) will reach US$2 Billion by the end of the analysis period. Increasing incidence of neurological diseases and expanding geriatric population, increasing spending on healthcare sector, positive reimbursement framework and presence of several leading industry players are fueling growth in the North America region. Asia-Pacific is poised to grow at a robust pace, driven by sizeable patient pool, favorable healthcare initiatives and high unmet healthcare needs. The Asia-Pacific market is expected to gain from notable surge in aging population, increasing awareness regarding neurological disorders, and rising incidence of cancer and osteoporosis. Select Competitors (Total 61 Featured)

Read the full report: https://www.reportlinker.com/p05957490/?utm_source=GNW

CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW Impact of Covid-19 and a Looming Global Recession 2020 Marked as a Year of Disruption & Transformation EXHIBIT 1: World Economic Growth Projections (Real GDP, Annual % Change) for 2019 to 2022 Global Nerve Repair & Regeneration Market Buckles under COVID- 19 Strain Covid-19 Patients in Prone Position Suffering Nerve Damage Bodes Well for Market Growth Nerve Repair and Regeneration Market Set for a Robust Growth Neurostimulation & Neuromodulation Devices Hold Commanding Slot in Nerve Repair & Regeneration Market Biomaterials to Exhibit Rapid Growth Nerve Repair and Regeneration Market by Application US and Europe Dominate the Market Asia-Pacific and other Emerging Regions Display Impressive Growth Potential Recent Market Activity

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS High Incidence of Neurological Disorders: A Key Market Driver EXHIBIT 2: Annual Incidence of Adult-Onset Neurologic Disorders in the US Effects of COVID-19 on the Nervous System Sheds Focus on Neuromodulation Applications Increasing Cases of Peripheral Nerve Injuries Drive the Nerve Repair and Regeneration Market Growing Number of Vehicular Accidents Drive the Peripheral Nerve injuries Repair Market Rising Geriatric Population and Subsequent Growth in Prevalence of Neurological Disorders EXHIBIT 3: Global Population Statistics for the 65+ Age Group in Million by Geographic Region for the Years 2019, 2025, 2035 and 2050 Growing Incidence of Neurodegenerative Diseases Propels the Market for Deep Brain Stimulation Devices EXHIBIT 4: Global Alzheimers Prevalence by Age Group EXHIBIT 5: Diagnosed Prevalence Cases of Parkinson?s Disease Across Select Countries EXHIBIT 6: Global DBS Market by Leading Player (2020E): Market Share Breakdown of Revenues for Medtronic, Boston Scientific, and Abbott Select Available Deep Brain Stimulation Devices Available in the Market Intensified Research Activity Across Various Neural Disciplines Induces Additional Optimism Stem Cell Therapy: A Promising Avenue for Nerve Repair and Regeneration Increasing Cases of Epilepsy Drives the Demand for Vagus Nerve Stimulation Devices EXHIBIT 7: Epilepsy Incidence by Type (2019): Percentage Share Breakdown for Idiopathic and Symptomatic Epilepsy EXHIBIT 8: Symptomatic Epilepsy Incidence by Type (2019): Percentage Share Breakdown of Congenital, Degenerative, Infective, Neoplastic, Trauma, and Vascular Epilepsy Spinal Cord Injuries Propel the Demand for Spinal Cord Stimulation Devices Recent Developments in Spinal Cord Injury Treatment Biomaterials (Nerve Conduits and Nerve Wraps) to Witness Rapid Growth New Biomaterials Pave the Way for Innovative Neurodegeneration Therapies Role of Nerve Conduits in the Treatment of Peripheral Nerve Injury Innovative Nerve Conduits from Stryker TENS (Transcutaneous electrical nerve stimulation devices) Market Witnesses Rapid Growth Non-Invasiveness of TMS (Transcranial Magnetic Stimulation) Propelling the adoption of TMS devices Nerve Grafts for Bridging Larger Nerve Gaps Role of Nerve Grafting in Treatment of Peripheral Nerve Injuries FDA-approved Nerve Tubes for Peripheral Nerve Repair

4. GLOBAL MARKET PERSPECTIVE Table 1: World Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 2: World Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 3: World 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 5: World Historic Review for Neurostimulation & Neuromodulation Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 6: World 15-Year Perspective for Neurostimulation & Neuromodulation Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 8: World Historic Review for Biomaterials by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Biomaterials by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 11: World Historic Review for Neurostimulation & Neuromodulation Surgeries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 12: World 15-Year Perspective for Neurostimulation & Neuromodulation Surgeries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 13: World Current & Future Analysis for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 14: World Historic Review for Neurorrhaphy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 15: World 15-Year Perspective for Neurorrhaphy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 17: World Historic Review for Nerve Grafting by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Nerve Grafting by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 19: World Current & Future Analysis for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 20: World Historic Review for Stem Cell Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Stem Cell Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 22: World Current & Future Analysis for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 23: World Historic Review for Hospitals & Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Hospitals & Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 26: World Historic Review for Ambulatory Surgery Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 27: World 15-Year Perspective for Ambulatory Surgery Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES Table 28: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 29: USA Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 30: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 31: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 32: USA Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 33: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 34: USA Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 35: USA Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 36: USA 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CANADA Table 37: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 38: Canada Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 39: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 40: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 41: Canada Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 42: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 43: Canada Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 44: Canada Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 45: Canada 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

JAPAN Table 46: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 47: Japan Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 48: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 49: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 50: Japan Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 51: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 52: Japan Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 53: Japan Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 54: Japan 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

CHINA Table 55: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 56: China Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 57: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 58: China Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 59: China Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 60: China 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 61: China Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 62: China Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 63: China 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

EUROPE Table 64: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2020 through 2027 and % CAGR

Table 65: Europe Historic Review for Nerve Repair and Regeneration Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 66: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027

Table 67: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 68: Europe Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 69: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 70: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 71: Europe Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 72: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 73: Europe Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 74: Europe Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 75: Europe 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

FRANCE Table 76: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 77: France Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 78: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 79: France Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 80: France Historic Review for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 81: France 15-Year Perspective for Nerve Repair and Regeneration Devices by Application - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy for the Years 2012, 2020 & 2027

Table 82: France Current & Future Analysis for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 83: France Historic Review for Nerve Repair and Regeneration Devices by End-Use - Hospitals & Clinics and Ambulatory Surgery Centers Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 84: France 15-Year Perspective for Nerve Repair and Regeneration Devices by End-Use - Percentage Breakdown of Value Sales for Hospitals & Clinics and Ambulatory Surgery Centers for the Years 2012, 2020 & 2027

GERMANY Table 85: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

Table 86: Germany Historic Review for Nerve Repair and Regeneration Devices by Product - Neurostimulation & Neuromodulation Devices and Biomaterials Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2019 and % CAGR

Table 87: Germany 15-Year Perspective for Nerve Repair and Regeneration Devices by Product - Percentage Breakdown of Value Sales for Neurostimulation & Neuromodulation Devices and Biomaterials for the Years 2012, 2020 & 2027

Table 88: Germany Current & Future Analysis for Nerve Repair and Regeneration Devices by Application - Neurostimulation & Neuromodulation Surgeries, Neurorrhaphy, Nerve Grafting and Stem Cell Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2020 through 2027 and % CAGR

View post:
Global Nerve Repair and Regeneration Devices Market to Reach $11. 8 Billion by 2026 - GlobeNewswire

Read More...

Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients – ScienceAlert

Wednesday, March 3rd, 2021

Spinal cord injuries are sustained by hundreds of thousands of people every year, with many patients experiencing a significant and often permanent loss of movement and physical sensation resulting from nerve damage.

Beyond intensive physical rehabilitation programs which can improve outcomes in some cases treatment options are virtually non-existent. But new results from a phase 2 clinical trial offer fresh hope for remedies on the horizon.

In an experimental collaboration by scientists in Japan and the US, 13 patients with spinal cord injuries (SCI)experienced a range of functional improvements in their condition after being treated with an intravenous infusion of their own stem cells, derived from their bone marrow.

The stem cells in question are known as mesenchymal stem cells (MSCs), which are multipotent adult stem cells with the ability to differentiate into a variety of cell types, enabling them to repair bone, cartilage, muscle, or fat tissue.

Despite the potential promise of these cells, their use as an actual therapy has generated considerable controversy, especially after Japan fast-tracked commercialisation approval in late 2018in advance of thorough data on the safety and effectiveness of the experimental treatment.

Over two years later, the researchers behind the therapy, called Stemirac, now have more of those data to share, and while it won't be enough to placate critics, the findings nonetheless offer valuable new information on what MSCs may do for patients with SCI.

"The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years," explains neurologist Stephen Waxman from Yale University, a senior author of the study .

"Now we have a hint, in humans, that it may be possible."

In the study, the researchers point out that while other trials have also looked at using MSCs to treat SCI via injection methods, their own technique, using intravenous infusion, could have particular benefits.

"Importantly, intravenously infused MSCs may affect not only the injury site, but other parts of the central nervous system including brain and blood vessels," the authors explain in their paper.

Whether that explains some of the results seen in their 13 patients is unclear, but the outcomes themselves are notable.

Of the individuals treated with Stemirac, all of whom had non-penetrative SCIs (meaning their spinal cords were not severed) sustained during serious physical accidents, all but one had demonstrated improvements in key sensory or motor functions by six months after the infusion.

Over half the group showed substantial improvements in things like walking ability or using their hands, and in many cases, graded improvements on a standardised impairment scale could be seen as soon as one day after the treatment, although other cases took weeks.

Significantly, no adverse effects were reported.

While the researchers acknowledge that theirs is a small trial with various limitations including the possibility that the recoveries seen may have been somewhat spontaneous they contend that the initial data show we're looking at something here that's safe, feasible, and worthy of follow-up studies with greater amounts of patients.

"Although this initial case study was unblinded and uncontrolled, the SCI patients appeared to demonstrate a tendency of relatively rapid improvement of neurological function that was often apparent within a few days following infusion of MSCs," the team writes.

As for how the MSC infusion delivers its healing, results from studies on animals have made the researchers think the stem cells secrete neural growth factors that restore important structures that reduce swelling, while restoring vital chemical activity.

In terms of the rapid improvements, the team suggests a chemical called brain derived neurotrophic factor (BDNF) may be involved, which is known to support the health of neurons via numerous mechanisms.

Hopefully, more research in the future can demonstrate the true extent of the potential benefits of this treatment.

The findings are reported in Journal of Clinical Neurology and Neurosurgery.

Visit link:
Controversial Stem Cell Therapy Has Helped Repair Injured Spinal Cords in 13 Patients - ScienceAlert

Read More...

Cynata tests wound dressing tech for stem cell therapy delivery – The West Australian

Wednesday, March 3rd, 2021

ASX-listed Cynata Therapeutics has signed an MoU with TekCyte Pty Ltd to access its wound dressing technology in the hope of commercialising TekCytes proprietary surface modifications of polymer-coated dressings for the delivery of Cynatas mesenchymal stem cells, or MSC, to wounds.

The Melbourne-based clinical-stage stem cell and regenerative medicine company is specifically looking to use TekCytes technologies in the commercial development of Cynatas MSC product for the treatment of diabetic foot ulcers.

Cynata said its trademarked Cymerus MSCs have already demonstrated promising efficacy in a pre-clinical model of diabetic wounds, often referred to as diabetic ulcers, utilising TekCytes dressing when seeded with MSCs or similar cells.

The company now plans to build on the solid pre-clinical foundation by conducting a clinical trial of its Cymerus MSC product on patients with diabetic foot ulcers using an active dressing supplied by TekCyte.

Cynata expects to start the clinical trial as soon as possible after it completes negotiations with TekCyte on a formal license agreement.

The company says diabetic foot ulcers are a significant medical problem with an estimated market value of nearly US$10 billion based on data sourced from Transparent Market Researchs review of the global diabetic foot ulcers treatment market out to 2027.

In Australia alone, diabetic foot disease results in more than 27,000 hospitalisations, 4,400 amputations and 1,700 deaths annually. Unfortunately, there is also evidence that the burden of this disease is growing year-on-year, and existing treatment options have limited success.

The very encouraging data from the pre-clinical studies at the CTM-CRC with our Cymerus MSC product, especially when compared with other cell products, provides a rational and sound basis for us to proceed with TekCytes patch technology.

Elsewhere in Cynatas labs and clinical trial sites, the company is working to deploy its stem cell technology across a range of ailments, including Osteoarthritis, renal transplantation, idiopathic pulmonary fibrosis and even COVID-19.

Stem cells, most familiar as embryonic stem cells, are special human cells capable of morphing into all other cell varieties from muscles to brain cells.

Whilst stem cell technology has been developing for a decade or two now, it has been routinely based on using hematopoietic stem cells to treat disease. However, a donor can currently transplant these cells only if a perfect match is available.

Instead of the arduous process of undertaking donor match searches, Cynata believes plentiful stem cells can be derived another way. By transforming adult stem cells with a type of genetic reprogramming, the company says it can create pluripotent stem cells that are capable of operating identically to the valuable embryonic cells.

The companys proprietary Cymerus technology uses pluripotent cells combined with a precursor cell called mesenchymoangioblasts, or MCA to fabricate numerous cell therapy products, including mesenchymal stem cells or MSCs.

Importantly, Cynata says it can produce those essential cells at a commercial scale, forgoing the need for multiple donors and conquering the usual supply bottlenecks currently frustrating stem cell therapies and researchers worldwide.

Other candidate diseases facing this potentially boundless technology include asthma, heart attack, sepsis, acute respiratory distress syndrome, or ARDS and cytokine release syndrome.

Plans are already well advanced for further clinical trials of the fascinating Cymerus MSC products in Graft-versus-host Disease, or GvHD through licensee Fujifilm.

GvHD is an all-too-common consequence of traditional stem cell therapies and is one of the earliest ailments to be attacked by Cynatas technology.

Cynata looks to be hurtling down a path to turn science fiction into reality by developing a wound patch that can effectively regenerate the bodys own cells a bit more than just a band-aid approach, perhaps?

Is your ASX-listed company doing something interesting? Contact: matt.birney@wanews.com.au

Original post:
Cynata tests wound dressing tech for stem cell therapy delivery - The West Australian

Read More...

Stem Cell Injections Could Treat Spinal Cord Injuries | IE – Interesting Engineering

Wednesday, March 3rd, 2021

Injecting bone marrow stem cells in patients with spinal cord injuries significantly improved their motor functions.

Scientists from Yale University and Sapporo Medical University in Japan reported their findings in the Journal of Clinical Neurology and Neurosurgery on February 18.

The stem cells were prepared from the patients' own bone marrow, and injected intravenously back into the patients, with no side effects from the therapy noted by the researchers. This was not a blind trial, and no placebos were administered.

Over half of the patients reported improved motor functions within weeks of the injections. Key motor functions include walking and using hands.

The patients in question had experienced non-penetrating spinal cord injuries a few weeks prior to the study, which were caused by minor falls or trauma. These injuries left them without motor function or coordination, sensory loss, and bowel and bladder dysfunction.

This type of therapy isn't only ideal for spinal cord injuries, but also for brain injuries, such as strokes. As Jeffery Kocsis of Yale University said "Similar results with stem cells in patients with stroke increases our confidence that this approach may be clinically useful."

Adding to this comment, Stephen Waxman from Yale University said "The idea that we may be able to restore function after injury to the brain and spinal cord using the patients own stem cells has intrigued us for years. Now we have a hint, in humans, that it may be possible."

It's still the early days of this stem cell therapy for spinal cord injuries, and the authors of the study stress that further studies need to be carried out before confirming the results of their initial, unblinded trial something that could take years.

It's still exciting news, as stem cell therapy has been researched for years as a potential remedy for such injuries. Just last year, the Mayo Clinic carried out trials on stem cell therapy for spinal cord injuries. While in Japan, a few eyebrows were raised in 2019 as the nation accepted stem cell therapy to treat spinal cord injuries, perhaps a little prematurely some scientists suggested in the journal Nature.

Continue reading here:
Stem Cell Injections Could Treat Spinal Cord Injuries | IE - Interesting Engineering

Read More...

NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T – PharmiWeb.com

Wednesday, March 3rd, 2021

Theglobal Canine Arthritis Treatment Marketis expected to reachUS$ 3051.8 Mnby 2028, growing at a moderate CAGR of 4.4%, as per a market intelligence outlook by Future Market Insights, a premier market research firm delivering actionable insights to key leaders across the globe. Mostly found in ageing canines, canine arthritis is a degenerative condition that results in joints inflammation and progresses with time if left untreated. The condition further worsens resulting in associated conditions like osteoarthritis, osteophytosis, and loss of cartilage, in response to pain and inflammation. Injuries, obesity, and poor bone development often leads to canine arthritis.

Rising number of chronic diseases in dogs, globally, is the primary factor driving canine arthritis treatment adoption. Additional factors like increasing number of veterinary clinics couple with stem cell transplants and Non-steroidal anti-inflammatory medications (NSAIDs) are likely to push the market for canine arthritis treatment. Non-steroidal anti-inflammatory medications (NSAIDs) segment is expected to made substantial revenue contribution to overall canine arthritis treatment market followed by opioids during forecast period.

North America, followed byEuropeandAsia Pacific, is expected to be largest consumer of canine arthritis treatment drugs and therapies, owing to existence of developed regulations and superior healthcare infrastructure. For more collaborative research in the canine arthritis market,JapanandSpainare projected to be promising markets.

A sample of this report is available upon request @https://www.futuremarketinsights.com/reports/sample/rep-gb-3552

Use of NSAIDs to Further Shape Canine Arthritis Market

Ease of FDA approval for novel and innovative canine arthritis treatment drugs coupled with growing adoption of canine stem therapy to treat arthritis and huge investments in research and development for the production of NSAIDs and opioids indicated for arthritis especially in European countries is projected to projected to present opportunities to canine arthritis treatment product manufacturers.

The focus presently is on developing high grade NSAIDs, as these drugs are frequently used to manage canines condition-offering a dramatic improvement in mobility and quality of life. The demand for NSAIDs in on a perpetual rise as it lowers the production of prostaglandins-associated with driving inflammation leading to arthritis. In terms of treatment, NSAIDs are continue to be the globally accepted mainstay of pharmaceutical treatment for canine arthritis, further shaping the canine arthritis treatment market. Research suggests that more than 60% of canines above the age of 7, suffer from degenerative joint diseases.

According to a Healthcare Expert at Future Market Insights, Factors such as growing prevalence of chronic diseases in dogs, rising pets adoption, increased consumer spending on veterinary care and fast FDA approvals for drugs used for canine arthritis treatments are expected to boost the global canine arthritis treatment market during the forecast period. Additionally, canine owners opting for canine stem cell therapy over drug medicines is the most lucrative segment in terms of investment opportunities. However, safety issues affecting clinical efficacy of canine pluripotent cells and high therapy costs limit the adoption of canine stem cell therapy. FDA-approved MediVets Autologous Stem Cell and Aratanas Galliprant to control pain and inflammation associated with arthritis, are expected to contribute to the growth of the canine arthritis treatment market.

However, illicit drugs that are falsely registered could restrain the canine treatment market. Such drugs are not manufactured in accordance with regulations, inversely affecting the dogs health coupled with sales of approved drugs. Research shows that counterfeit medicines are more prevalent in under-developed and developing countries. Growing international trade and ecommerce penetrations are fuelling the sales of sub-standard medicine.

Get Access to Research Methodology Prepared by Experts>>>https://www.futuremarketinsights.com/ask-question/rep-gb-3552

Canine Insurances & Direct Drug Sales to Open Canine Arthritis Treatment Opportunities

Pet insurance is an upcoming trend, especially in mature economies. With only 1% dogs insured in the US, the trend is catching up in the region, opening up opportunities for veterinary insurance vendors. However, this number is as high as 50% for pet dogs in some European countries. Moreover, introduction of third-party payers is expected to boost the turnover of the canine arthritis drugs, mostly for the NSAIDs and stem cell therapy segments globally, and lead to build-up of new sales channels for drugs treating canine arthritis.

Also, canine healthcare products manufacturers are relying on direct sales to end-users in a bid to reach out to a larger consumer base. Furthermore, by adopting this sales route, companies are also providing additional training and support in terms of disease management and adherence to treatment protocols.

Key players including Boehringer Ingelheim, Elanco (Eli Lilly and Company), Zoetis Inc., Bayer AG, Aratana Therapeutics Inc., Vetoquinol S.A., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc are developing cost-effective drugs for canine arthritis treatment and increasing sales through acquisitions to enhance their respective market share. Manufacturers are also focusing in developing novel stem cell therapies for treating arthritis. Moreover, companies are focusing partnering with wholesalers, distributors and other channel partners to gain ownership over value chain.

Preview Analysis OnCanine Arthritis Treatment Market Segmentation By treatment type Non-steroidal anti-inflammatory drugs, Opioids, Stem Cell Therapy; route of administration Oral, Injectable:https://www.futuremarketinsights.com/reports/canine-arthritis-market

More from Healthcare, Pharmaceuticals and Medical devices:

Original post:
NSAIDs to Treat Arthritic Canines Through 2028; Stem Cell Therapies to Invigorate Canine Arthritis T - PharmiWeb.com

Read More...

Overview of stem cells therapy in amyotrophic lateral sclerosis – DocWire News

Wednesday, March 3rd, 2021

This article was originally published here

Neurol Res. 2021 Feb 25:1-17. doi: 10.1080/01616412.2021.1893564. Online ahead of print.

ABSTRACT

Background: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease of upper and lower motor neurons with high burden on society. Despite tremendous efforts over the last several decades, there is still no definite cure for ALS. Up to now, only two disease-modifying agents, riluzole and edaravone, are approved by U.S. Food and Drug Administration (FDA) for ALS treatment, which only modestly improves survival and disease progression. Major challenging issues to find an effective therapy are heterogeneity in the pathogenesis and genetic variability of ALS. As such, stem cell therapy has been recently a focus of both preclinical and clinical investigations of ALS. This is because stem cells have multifaceted features that can potentially target multiple pathogenic mechanisms in ALS even though its underlying mechanisms are not completely elucidated. Methods & Results: Here, we will have an overview of stem cell therapy in ALS, including their therapeutic mechanisms, the results of recent clinical trials as well as ongoing clinical trials. In addition, we will further discuss complications and limitations of stem cell therapy in ALS. Conclusion: The determination of whether stem cells offer a viable treatment strategy for ALS rests on well-designed and appropriately powered future clinical trials. Randomized, double-blinded, and sham-controlled studies would be valuable.

PMID:33632084 | DOI:10.1080/01616412.2021.1893564

Read the original:
Overview of stem cells therapy in amyotrophic lateral sclerosis - DocWire News

Read More...

We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients – RT

Wednesday, March 3rd, 2021

Using a somewhat controversial stem cell therapy, a joint team of Japanese and US-based researchers have successfully repaired some damage in 13 patients with spinal cord injuries (SCI).

SCIs can often cause permanent loss of movement and physical sensation from resultant nerve damage. While physical rehabilitation programs can partially improve outcomes, actual treatment and recovery of lost mobility and function is nigh on impossible. Until now, perhaps.

According to new results from a phase 2 clinical trial conducted in an experimental collaboration by scientists in Japan and the US, patients treated with an intravenous infusion of their own mesenchymal stem cells (MSCs), harvested from their bone marrow, saw significant functional improvements.

MSCs are adult stem cells with the uncanny ability to morph into numerous different cell types, affording them the ability to repair different tissues in the human body, ranging from bone and cartilage to muscle or other tissues.

In 2018, Japan fast-tracked commercial approval of the treatment, opting to forego full testing and regulatory approval despite a lack of complete data on its safety and efficacy. This was much to the consternation of the medical industry at large, and caused considerable controversy in the process.

Fast-forward to the present day and the therapy, called Stemirac, may prove revolutionary in treating non-penetrative SCIs, in which the spinal cord is damaged but remains intact.

In the trials, all 13 patients demonstrated improvements in sensory and motor function six months after they received their infusion, while more than 50 percent of the participants saw substantial improvements in motor function, including walking within a day, though for others it took weeks.

"The idea that we may be able to restore function after injury to the brain and spinal cord using the patient's own stem cells has intrigued us for years," explains neurologist Stephen Waxman from Yale University, a senior author of the study.

"Now we have a hint, in humans, that it may be possible."

Other research has examined the efficacy of injected MSCs to treat SCI, but this new method involves intravenous infusion, which operates in a different way and, so far, has no adverse effects. Still, the researchers acknowledge the limited scope of the trial, as well as the fact that it was unblinded and uncontrolled.

"Importantly, intravenously infused MSCs may affect not only the injury site, but other parts of the central nervous system including brain and blood vessels," the authors explain in their paper.

For now, they suspect the stem cells secrete neural growth factors, particularly brain-derived neurotrophic factor (BDNF), which have a restorative as well as anti-inflammatory effect. While a lot more research is needed to determine the long term safety and efficacy of the treatment, it could one day prove revolutionary.

Think your friends would be interested? Share this story!

More:
We have a hint it may be possible: Controversial stem cell therapy repaired injured spinal cords in 13 patients - RT

Read More...

Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -…

Wednesday, March 3rd, 2021

Global Stem Cell Therapy Market 2021 Research Report Including Pre COVID-19 and Post COVID-19 Market Scenario

The recent corona crisis (COVID-19) has disrupted national and international Stem Cell Therapy business, adversely affecting the current and future activities of the Stem Cell Therapy industry. It will have a direct and indirect impact on Stem Cell Therapy industry stakeholders and its integrated industries. The significant impact from the COVID-19 lockdown will be on Stem Cell Therapy consumption. Given the current market conditions, the virus is rapidly changing the consumption and supply chain of companies in the market.Global marketers have observed in the latest market intelligence survey that the global Stem Cell Therapy market will record a value of about US $ xx Mn in 2019 and will grow at a CAGR of xx% during the estimated period 2020-2027. In terms of product type, the segment has a significant share of end applications. All Stem Cell Therapy consumption trends and recruitment patterns are listed in the report.

GetFree Sample [emailprotected]https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027#request-sample

Global Stem Cell Therapy Market Key Players:

Segments of the Stem Cell Therapy Report:

Market Segment By Type:

Market Segment By Application

Stem Cell Therapy Market analysis report helps you with intelligent decision-making and better manages the marketing of goods and services leading to business growth. The Stem Cell Therapy Market report looks at the market in terms of general market conditions, industry improvement, market scenario, development, cost and profit in specific market regions, position among key players, and comparative prices. The data and information contained in this Stem Cell Therapy Market business report not only helps businesses make data-driven decisions but also ensures maximum return on investment (ROI).

Do Inquiry Before Purchasing Report Here and Ask For Discount https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027#inquiry-before-buying

The Stem Cell Therapy Industry Report provides in-depth analysis and insights into the developments impacting business and enterprises at the global and regional level. This research report presents a detailed analysis of the key trends, drivers, constraints, and opportunities influencing sales growth. This study focuses on the global Stem Cell Therapy market by share, volume, value, and shape by region along with type and application.

The geographical analysis covers the following regions: North America Europe Asia Pacific Latin America Middle East and Africa

Stem Cell Therapy Market Research provides the following information In-depth analysis of drivers, constraints, opportunities, and trends influencing the growth of the global Stem Cell Therapy market. Important analysis of the Stem Cell Therapy market by product type and end-use industry. Thorough understanding of the strengths, weaknesses, opportunities, and threats of various Stem Cell Therapy market players. Accurate year-on-year growth of the global Stem Cell Therapy market in terms of value and size.

Key questions answered in this report are: What was the global market size in 2019? What is the market size of the different regions and countries around the world? What factors contribute to the development and what are the constraints on development? What types of applications and products are covered in this report? How can market forecasting statistics help the industry growth? What are the potential investment possibilities of the market in other countries/regions?

Browse Detailed Description, TOC, Detailed Segment analysis, Table Of Figures, https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#table-of-contents

https://neighborwebsj.com/

Originally posted here:
Global Stem Cell Therapy Market 2021- Regional Analysis(Consumption, Revenue, Market Share and Growth Rate) and Forecast Till 2027 NeighborWebSJ -...

Read More...

Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU…

Wednesday, March 3rd, 2021

MarketQuest.biz has presented updated research report titled Global Animal Stem Cell Therapy Market 2020 by Manufacturers, Type and Application, Forecast to 2025 which presents vital answers and interpretations concerning market growth and developments in the market. The report contains insightful information like market share, market size, and growth rate, as well as several challenges and ingrained threats and limitations that have interrupted normal growth prognosis in global Animal Stem Cell Therapy market. The report analyzes the segment expected to dominate the industry and market.This market report includes quantitative and qualitative estimation by industry experts, the contribution from industry across the value chain. The report gives information about the supply and demand situation, the competitive scenario, market opportunities, and the threats faced by key players.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Competitive Intelligence:

The leading players are covered in the global Animal Stem Cell Therapy market report with product description, business outline, as well as production, future demand, company profile, product portfolio, product/service price, capacity, sales, and cost. So the entire information related to the company concerning the specific product and in-depth information of collaborations and all other essential information is added in the research report.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketquest.biz/sample-request/13731

Report has been segmented into geographical segmentation, key players, key topics industry value and demand analysis and forecast and gives comprehensive investigation.The report provides knowledge of the key product segments and their future by having complete insights of market and by making in-depth analysis of market segments. Report includes supply-demand statistics, and segments that constrain the growth of an industry. It also includes raw materials used and manufacturing process of global Animal Stem Cell Therapy market.

All top players actively involved in this industry are as follows: Medivet Biologics LLC, Kintaro Cells Power, U.S. Stem Cell, Inc, VETSTEM BIOPHARMA, Magellan Stem Cells, J-ARM, Animal Cell Therapies, Celavet Inc., VetCell Therapeutics, Animal Stem Care, Cell Therapy Sciences, Animacel

The report highlights product types which are as follows:Dogs, Horses, Others

The report highlights top applications which are as follows:Veterinary Hospitals, Research Organizations

Promising regions & countries mentioned in the global Animal Stem Cell Therapy market report:North America (United States, Canada and Mexico), Europe (Germany, France, United Kingdom, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina), Middle East & Africa (Saudi Arabia, UAE, Egypt and South Africa)

Market By Manufacturing Cost Analysis:

The study report includes key raw materials analysis, the price trend of key raw materials, key suppliers of raw materials, market concentration rate of raw materials, the proportion of manufacturing cost structure, and manufacturing process analysis. Moreover, the report evaluates the product pricing, production capacity, demand, supply, as well as the historical performance of the global Animal Stem Cell Therapy market.

ACCESS FULL REPORT: https://www.marketquest.biz/report/13731/global-animal-stem-cell-therapy-market-2020-by-manufacturers-type-and-application-forecast-to-2025

Report Offerings:

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketquest.biz

Read the original post:
Global Animal Stem Cell Therapy Market 2020 2025 Research Report Segment Outlook, Growth Potentials and Analysis of COVID-19 Worldwide Outbreak KSU...

Read More...

Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network – The…

Wednesday, March 3rd, 2021

Request Download Sample Ask For Discount Company Profile

New Jersey, United States,-The Animal Stem Cell Therapy Market report provides in-depth knowledge and insights into the Animal Stem Cell Therapy market in terms of market size, market share, factors influencing growth, opportunities, and current and emerging trends. The report has the updated and latest information on the Animal Stem Cell Therapy market that has been further validated and verified by industry experts and professionals. The Animal Stem Cell Therapy market report provides historical, current, and forecast estimates of sales generation and profit for each segment and sub-segment of the Animal Stem Cell Therapy market in every key region around the world. The report also highlights the emerging growth opportunities in the business that are designed to support market growth.

The latest report is the latest study to offer 360 coverage of the Animal Stem Cell Therapy industry, which is facing the worst negative economic impact of the COVID-19 outbreak since the beginning of this year.

The report covers the following key players in the Animal Stem Cell Therapy Market:

Medivet Biologics LLC VETSTEM BIOPHARMA J-ARM U.S. Stem Cell Inc VetCell Therapeutics Celavet Inc. Magellan Stem Cells Kintaro Cells Power Animal Stem Care Animal Cell Therapies Cell Therapy Sciences Animacel

Segmentation of Animal Stem Cell Therapy Market:

The report provides an in-depth analysis of various market segments based on the product line, applications, major regions, and key companies in the industry. In addition, the report has a single section that provides a detailed analysis of the manufacturing process and includes information gathered from primary and secondary data collection sources. The main source for data collection is interviews with industry experts who provide accurate information about the future market scenario.

By the product type, the market is primarily split into:

Dogs Horses Others

By the application, this report covers the following segments:

Veterinary Hospitals Research Organizations

Animal Stem Cell Therapy Market Report Scope

Animal Stem Cell Therapy Geographic Market Analysis:

The latest business intelligence report analyzes the Animal Stem Cell Therapy market in terms of market reach and customer base in key geographic market regions. The Animal Stem Cell Therapy market can be geographically divided into North America, Asia Pacific, Europe, Latin America, the Middle East, and Africa. This section of the report provides an accurate assessment of the Animal Stem Cell Therapy market presence in the major regions. It defines the market share, market size, sales, distribution network and distribution channels for each regional segment.

Key Points of theGeographical Analysis:

** Data and information on consumption in each region** The estimated increase in consumption rate** Proposed growth in market share for each region** Geographic contribution to market income** Expected growth rates of the regional markets

Key Highlights of the Animal Stem Cell TherapyMarket Report:

** Analysis of location factors** Raw material procurement strategy** Product mix matrix** Analysis to optimize the supply chain** Patent analysis** R&D analysis** Analysis of the carbon footprint** Price volatility before commodities** Benefit and cost analysis** Assessment and forecast of regional demand** Competitive analysis** Supplier management** Mergers and acquisitions** Technological advances

Visualize Animal Stem Cell Therapy Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

About Us: Verified Market Reports

Verified Market Reports is a leading Global Research and Consulting firm servicing over 5000+ global clients. We provide advanced analytical research solutions while offering information-enriched research studies.

We also offer insights into strategic and growth analyses and data necessary to achieve corporate goals and critical revenue decisions.

Our 250 Analysts and SMEs offer a high level of expertise in data collection and governance using industrial techniques to collect and analyze data on more than 25,000 high-impact and niche markets. Our analysts are trained to combine modern data collection techniques, superior research methodology, expertise, and years of collective experience to produce informative and accurate research.

Our research spans over a multitude of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages etc. Having serviced many Fortune 2000 organizations, we bring a rich and reliable experience that covers all kinds of research needs.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website: https://www.verifiedmarketreports.com/

Read the rest here:
Animal Stem Cell Therapy Market Size 2021 | Global Trends, Business Overview, Challenges, Opportunities and Forecast to 2027 The Bisouv Network - The...

Read More...

Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network – The Bisouv…

Wednesday, March 3rd, 2021

The Stem Cell Therapy Market research report represents a detailed analysis of the future scope, market numbers, revenue, market share, and growth factors for the historic and forecast period 2015-2027. Download a free sample report for a better understanding (Get Free Sample Report)

The Global Stem Cell Therapy Industry Research Report covers 360 degree fundamental market statistics. The competitive structure, market size, market share, revenue analysis and trends are explained in detail in this study. It reflects the product portfolio, specifications, industry plans and policies, and market scope. This is a comprehensive survey that includes a analysis of major player and their market size, share, Business Overview, growth, revenue, compnay profile, Product Profiles, Application and Specification, growth strategies, Market Performance (2015-2020).

This report considers the worlds top players in the industry.

Key PLayers:

This report will help you understand how COVID-19 affected the growth, revenue and more of the Stem Cell Therapy market in 2019-2020 (1st, 2nd, 3rd and 4th quarters). This includes historical and forecast data from 2015 to 2027.

Download Free Sample Including COVID-19 Impact Analysis, TOC, TOF, Charts, Graphs, Detailed Segment Analysis, Key Players Analysis(SWOT & Porters 5 Forces Analysis):https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#request-sample

The report begins with a Stem Cell Therapy industry definition and scope that lists product definitions, product types, growth rates, and market size estimates. Market concentration and maturity are taking place in North America, Europe, the Middle East, Africa, Asia Pacific, South America and other regions. The report is segmented based on three key aspects: Stem Cell Therapy type, wide range of product applications, and region. In addition, these top regions are subdivided as follows to provide a country-level analysis of the above regions.

The following section describes import/export details, SWOT analysis, and Stem Cell Therapy industry conditions. Describes a detailed analysis of competitor profiles. The Competitive Profile section displays Stem Cell Therapy market presentations, product details, market value, prices and gross profit for 2019. This report details the Stem Cell Therapy new product launches, mergers and acquisitions, plans and industry policies.

Market Segmentation:

Market By Type:

Market By Application:

Region segment covered

North Americao U.S.o Canada Europeo U.K.o Germanyo Franceo Rest of Europe Asia Pacifico Chinao Japano Indiao Rest of Asia Pacific Latin Americao Brazilo Argentinao Rest of Latin America Middle East and Africao Saudi Arabiao UAEo Turkeyo Rest of Middle East and Africa

Browse Detailed Description, TOC, Detailed Segment analysis, Table Of Figures, https://globalreports.biz/product/stem-cell-therapy-market-size-share-growth-trends-and-covid-19-impact-analysis-report-segmented-by-type-application-end-user-region-%c2%96-global-forecast-to-2027/#table-of-contents

Link:
Projected Stem Cell Therapy Market Growth After Coronavirus COVID-19 Outbrek Analysis and Forecast (2020-2027) The Bisouv Network - The Bisouv...

Read More...

Page 11234..1020..»


2021 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick